# Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

> **NCT00678587** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 292 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis
- Chronic Liver Disease
- HCV
- NASH - Nonalcoholic Steatohepatitis
- HIV Infection
- Thrombocytopenia
- Hepatitis C Virus
- HBV
- Human Immunodeficiency Virus
- Liver Diseases
- Hepatitis B Virus

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00678587
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 292 (ACTUAL)
- **Why stopped:** GSK decision
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678587, "Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00678587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*